Breakthrough nocardiosis emerged despite standard prophylaxis in a kidney transplant recipient
A 39-year-old renal transplant recipient in India developed disseminated nocardiosis while taking trimethoprim/sulfamethoxazole prophylaxis, exposing a failure mode that remains easy to miss in immunosuppressed patients. Her illness began after 14 months of clinical stability on tacrolimus, mycophenolate sodium, prednisolone, and cotrimoxazole prophylaxis. Fever, hemoptysis, anorexia, and weight loss evolved over 45 days, and the first chest computed tomography showed right upper lobe consolidation with pleural effusion. Lung biopsy and microbiology initially established invasive pulmonary aspergillosis, so the early diagnostic frame centered on fungal disease rather than a second opportunistic pathogen.
The trajectory changed when neurologic findings appeared. Altered sensorium and bilateral lower-limb weakness forced escalation, because pulmonary disease in a transplant recipient rarely stays confined to the lung when symptoms spread to the central nervous system. Brain imaging then revealed multiple ring-enhancing supratentorial lesions with central diffusion restriction and perilesional edema, a pattern that strongly favored abscess-like infection over a neoplastic process. Nocardia has a predilection for the brain in immunocompromised hosts, and hematogenous dissemination explains why pulmonary disease can become a multisystem emergency with little warning.
Mixed opportunistic infection delayed the complete diagnosis
Physical examination at referral showed asymmetric upper motor neuron weakness in the lower limbs, neck stiffness, and coarse bilateral crackles. Repeat transbronchial lung biopsy provided the turning point: suppurative inflammation with weakly acid-fast, branching, beaded filamentous organisms on Fite stain and hematoxylin and eosin stain. Culture on Sabouraud dextrose agar yielded dry, chalky colonies consistent with Nocardia species. Species-level identification could not be completed because matrix-assisted laser desorption/ionization time-of-flight mass spectrometry failed twice and 16S rRNA sequencing was not available. In a setting where morphology suggests the diagnosis but advanced confirmation is incomplete, treatment decisions depend heavily on susceptibility data and bedside judgment.
The laboratory profile carried direct therapeutic consequences. Disc diffusion on cation-adjusted Mueller-Hinton agar, interpreted with Comité de l’Antibiogramme de la Société Française de Microbiologie thresholds, showed resistance to cotrimoxazole and ciprofloxacin, but susceptibility to linezolid, minocycline, imipenem, and amikacin. Resistance to the very agent commonly used for prophylaxis and treatment matters because trimethoprim/sulfamethoxazole has long been the default defense against nocardiosis in transplant recipients. Once the organism bypasses that barrier, empiric therapy becomes unreliable, especially in a patient already burdened by concurrent invasive aspergillosis.
Targeted therapy produced clinical recovery and radiologic clearance
The diagnosis of disseminated trimethoprim/sulfamethoxazole-resistant nocardiosis with pulmonary and cerebral involvement led to immediate changes in management. Tacrolimus and mycophenolate were withheld, low-dose prednisone was continued, and imipenem plus linezolid were started alongside voriconazole. Clinical response followed within 1 week, which is consistent with the principle that rapid suppression of bacterial burden can reverse encephalitic and pulmonary symptoms before irreversible tissue injury develops. After 1 month, cytopenias emerged, prompting a switch from linezolid to minocycline. Because of seizure risk, imipenem was changed to meropenem, and meropenem continued for 3 months with minocycline. Voriconazole was stopped after 6 months.
The outcome was unusually favorable for a disseminated infection in a transplant recipient. Imaging at 6 months showed complete radiological resolution of both pulmonary and intracranial lesions, and graft function remained preserved. At 1-year follow-up, the patient was still doing well and remained on secondary prophylaxis with minocycline. A one-sentence clinical reality sits beneath those numbers: the brain lesions cleared because therapy was not merely active in vitro, it was sustained long enough to sterilize a disseminated infection in a host whose immune system was deliberately suppressed.
Susceptibility testing is no longer optional when Nocardia breaks through prophylaxis
Trimethoprim/sulfamethoxazole resistance in Nocardia is being reported more often, but the apparent prevalence varies widely by geography, isolate source, and test method. One United States study found resistance in 42% of isolates to trimethoprim/sulfamethoxazole and 61% to sulfamethoxazole, while another analysis of 552 isolates across 6 reference laboratories found only 2% resistance, a discrepancy attributed to inter-laboratory variability and possible misreading of trailing MIC endpoints. Those conflicting results do not weaken the core message; they show how fragile susceptibility interpretation can be when laboratory expertise and reference standards are inconsistent.
India has reported a meaningful burden of resistant disease in renal transplant recipients. A renal-transplant series of 16 nocardiosis cases found that 9 patients were receiving cotrimoxazole prophylaxis and 4 N. farcinica isolates were resistant. A 10-year South India analysis reported 20.8% resistance among 48 cases. A North India center described nocardiosis in 12 renal transplant recipients, 60% of isolates were trimethoprim/sulfamethoxazole-resistant, and 7 of 12 patients had breakthrough infection while on prophylaxis. These reports fit the clinical pattern seen here: prophylaxis reduces risk but does not eliminate it, and resistance can convert what should be preventive therapy into a misleading sense of security.
Brain imaging should accompany pulmonary nocardiosis even without focal deficits
Pulmonary nocardiosis in transplant recipients can resemble bacterial pneumonia, fungal infection, or mycobacterial disease, and the overlap delays recognition. Central nervous system disease occurs in 20% to 44% of pulmonary cases, so brain imaging is warranted even when neurologic symptoms are absent. Disseminated nocardiosis carries high mortality in transplant recipients, with reported rates of 64% to 100%, which makes early detection especially important when the patient already has mixed opportunistic infection. Species identification remains another weak point because morphology and routine biochemical methods often fail, and matrix-assisted laser desorption/ionization time-of-flight mass spectrometry may be unavailable or inconclusive.
This case places several bedside lessons into one frame. Breakthrough nocardiosis can occur during standard prophylaxis. Resistance testing can redirect therapy toward agents such as linezolid, minocycline, and carbapenems. Brain imaging can uncover silent dissemination before irreversible neurologic decline. In a renal transplant recipient with pulmonary disease and evolving neurologic findings, the cost of assuming cotrimoxazole will remain active is measured in missed time, not just missed microbiology.